Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic

References

• Akacha, M., Branson, J., Bretz, F., Dharan, B., Gallo, P., Gathmann, I., Hemmings, R., Jones, J., Xi, D., and Zuber, E. (2020), “Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1788984.
   PubMed Web of Science ®Google Scholar
• Collins, S. H., and Levenson, M. S. (2020), “Comment on ‘Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic’,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1779123.
   Web of Science ®Google Scholar
• Degtyarev, E., Rufibach, K., Shentu, Y., Yung, G., Casey, M., Englert, S., Liu, F., Liu, Y., Sailer, O., Siegel, J., Sun, S., Tang, R., Zhou, J., and on behalf of the Industry Working Group on Estimands in Oncology (2020), “Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1785543..
   Web of Science ®Google Scholar
• Dequin, P. F., Le Gouge, A., Tavernier, E., Giraudeau, B., and Zohar, S. (2020), “Embedding a COVID-19 Group Sequential Clinical Trial Within an Ongoing Trial: Lessons From an Unusual Experience,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1800509.
   Web of Science ®Google Scholar
• Guo, T., Chen, C., Chiang, C., Chen, C.-T., and Hsiao, C.-F. (2020), “Operational Experiences in China and Statistical Issues on the Conduct of Clinical Trials During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1797866.
   Web of Science ®Google Scholar
• Hemmings, R. (2020), “Under a Black Cloud Glimpsing a Silver Lining: Comment on Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1785931.
   PubMed Web of Science ®Google Scholar
• ICH (2019), “Topic E9(R1) on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” available at www.ich.org.
   Google Scholar
• JPMA Data Science Expert Committee (2020), “COVID-19 [inline image] COVID-19 Pandemic-ka deno Rinshosiken-Jisshi nitaisuru Toukeitekikadai to Suisho (in Japanese) [Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic],” available at http://www.jpma.or.jp/medicine/shinyaku/tiken/allotment/pdf/covid-19_conduct-clinical-trials.pdf.
   Google Scholar
• Kunz, C. U., Jörgens, S., Bretz, F., Stallard, N., Van Lancker, K., Xi, D., Zohar, S., Gerlinger, C., and Friede, T. (2020), “Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1799857.
   PubMed Web of Science ®Google Scholar
• Meyer, R. D., Ratitch, B., Wolbers, M., Marchenko, O., Quan, H., Li, D., Fletcher, C., Li, X., Wright, D., Shentu, Y., Englert, S., Shen, W., Dey, J., Liu, T., Zhou, M., Bohidar, N., Zhao, P. L., and Hale, M. (2020), “Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1779122.
   PubMed Web of Science ®Google Scholar
• Nilsson, M., Crowe, B., Anglin, G., Ball, G., Munsaka, M., Shahin, S., and Wang, W. (2020), “Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1804444.
   Web of Science ®Google Scholar
• O’Kelly, M., and Li, S. (2020), “Assessing via Simulation the Operating Characteristics of the WHO Scale for COVID-19 Endpoints,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1811148.
   Web of Science ®Google Scholar
• Stallard, N., Hampson, L., Benda, N., Brannath, W., Burnett, T., Friede, T., Kimani, P. K., Koenig, F., Krisam, J., Mozgunov, P., Posch, M., Wason, J., Wassmer, G., Whitehead, J., Williamson, S. F., Zohar, S., and Jaki, T. (2020), “Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1790415..
   Web of Science ®Google Scholar
• Wiens, B. L., and Lipkovich, I. (2020), “The Impact of Major Events on Ongoing Noninferiority Trials, With Application to COVID-19,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1788983.
   Web of Science ®Google Scholar
• Zame, W. R., Bica, I., Shen, C., Curth, A., Lee, H. S., Bailey, S., Weatherall, J., Wright, D., Bretz, F., and van der Schaar, M. (2020), “Machine Learning for Clinical Trials in the Era of COVID-19,” Statistics in Biopharmaceutical Research, DOI: .10.1080/19466315.2020.1797867.
   Web of Science ®Google Scholar